Oncotarget

Research Papers:

TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis

Yang Zhang, Pengcheng Cai, Tao Liang, Lin Wang and Lihua Hu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:31705-31713. https://doi.org/10.18632/oncotarget.15954

Metrics: PDF 940 views  |   HTML 1562 views  |   ?  


Abstract

Yang Zhang1, Pengcheng Cai1, Tao Liang1, Lin Wang1,2 and Lihua Hu1

1Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

2Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Correspondence to:

Lihua Hu, email: lihuahu@hust.edu.cn

Lin Wang, email: katelinwang@126.com

Keywords: TIM-3, meta-analysis, solid tumor, prognostic marker, overall survival

Received: August 29, 2016     Accepted: February 21, 2017     Published: March 07, 2017

ABSTRACT

Accumulated studies have demonstrated the important role of T cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) in various solid tumors and indicated its correlation with patients’ survival. To further verify the prognostic significance of TIM-3 in cancer patients and its correlation with tumor, we performed this meta-analysis including seven studies searched from PubMed, Web of Science, and Embase till July 2016. A total of 869 patients were used to analyze the association between TIM-3 expression and patients’ overall survival (OS). The pooled results showed that higher expression of TIM-3 was significantly correlated to shorter OS (7 studies, HR=1.89; 95% CI: 1.38-2.57; P< 0.001). In addition, higher TIM-3 expression was associated with advanced tumor stage (3 studies, III/IV vs. I/II, RR=2.02; 95% CI: 1.45–2.81; P< 0.001). In conclusion, our study highlights the role of TIM-3 as a potential prognostic marker and a promising therapeutic target in solid tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15954